Methylation of the DLEC1 gene correlates with poor prognosis in Japanese lung cancer patients

Sasaki,Hidefumi; Hikosaka,Yu; Kawano,Osamu; Moriyama,Satoru; Yano,Motoki; Fujii,Yoshitaka

doi:10.3892/ol_00000050

Methylation of the DLEC1 gene correlates with poor prognosis in Japanese lung cancer patients

Authors:
- Hidefumi Sasaki
- Yu Hikosaka
- Osamu Kawano
- Satoru Moriyama
- Motoki Yano
- Yoshitaka Fujii
View Affiliations

Affiliations: Department of Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya 467-8601, Japan
Published online on: March 1, 2010 https://doi.org/10.3892/ol_00000050
Pages: 283-287

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The incidence of chromosome 3p gene alterations is one of the most frequent and earliest documented events in lung cancer. This study aimed to investigate promoter methylation in the deleted in lung and esophageal cancer 1 (DLEC1) gene, as well as the p16 and CDH1 genes in Japanese lung cancer cases. The methylation status of the promoter regions of DLEC1, p16 and CDH1 was investigated using methylation-specific PCR. The findings were compared to the clinicopathological features of lung cancer. Methylation-specific PCR showed that the DLEC1 promoter region was methylated in 65 out of 116 (56%) lung cancers. Patients with DLEC1-methylated cancer were associated with a significantly worse prognosis than those with unmethylated cancer (p=0.0368; hazard ratio=1.83). The p16 methylation status correlated with squamous histology (p=0.03) and smoking status (never smoker vs. smoker; p=0.0122). Patients with p16 ummethylated cancer harbored more EGFR mutations (p=0.0071). The CDH1 promoter region was hypermethylated in 65 out of 118 (55.1%) lung cancer cases. However, the CDH1 methylation status was not associated with the clinicopathological characteristics of the lung cancer types. p16 and CDH1 methylation status did not correlate with survival in the lung cancer patients. Thus, in our Japanese cohort, the methylation status of the DLEC1 gene was a marker of poor prognosis independent of stage.

View Figures

View References

1	Hung J, Kishimoto Y, Sugio K, et al: Allele-specific chromosome 3p deletions occur at an early stage in the pathogenesis of lung carcinoma. JAMA. 273:558–563. 1995. View Article : Google Scholar
2	Wistuba II, Behrens C, Virmani AK, et al: High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res. 60:1949–1960. 2000.
3	Zaborovsky ER, Lerman MI and Minna JD: Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. Oncogene. 21:6915–6935. 2002. View Article : Google Scholar : PubMed/NCBI
4	Qiu GH, Salto-Tellez M, Ross JA, et al: The tumor suppressor gene DLEC1 is frequently silenced by DNA methylation in hepatocellular carcinoma and induces G1 arrest in cell cycle. J Hepatol. 48:433–441. 2008. View Article : Google Scholar : PubMed/NCBI
5	Seng TJ, Currey N, Cooper WA, et al: DLEC1 and MLH1 promoter methylation are associated with poor prognosis in non-small cell lung carcinoma. Br J Cancer. 99:375–382. 2008. View Article : Google Scholar : PubMed/NCBI
6	Daigo Y, Nishiwaki T, Kawasoe T, Tamari M, Tsuchiya E and Nakamura Y: Molecular cloning of a candidate tumor suppressor gene, DLC1, from chromosome 3p. 213. Cancer Res. 59:1966–1972. 1999.PubMed/NCBI
7	Kwong J, Chow LS, Wong WK, et al: Epigenetic inactivation of deleted in lung and esophageal cancer 1 gene in nasopharyngeal carcinoma. Genes Chromosomes Cancer. 46:171–180. 2007. View Article : Google Scholar : PubMed/NCBI
8	Kwong J, Lee JY, Wong KK, et al: Candidate tumor-suppressor gene DLEC1 is frequently downregulated by promoter hypermethylation and histone hypoacetylation in human epithelial ovarian cancer. Neoplasia. 8:268–278. 2006. View Article : Google Scholar
9	Kang GH, Lee S, Cho NY, et al: DNA methylation profiles of gastric carcinoma characterized by quantitative DNA methylation analysis. Lab Invest. 88:161–170. 2008. View Article : Google Scholar : PubMed/NCBI
10	Japan Lung Cancer Society. General Rule for Clinical and Pathological Record of Lung Cancer. 5th edition. Jpn Lung Cancer Soc. 5. pp. 1–177. 1999
11	Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
12	Endo K, Konishi A, Sasaki H, et al: Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay. Lung Cancer. 50:375–384. 2005. View Article : Google Scholar : PubMed/NCBI
13	Sasaki H, Shimizu S, Endo K, et al: EGFR and erbB2 mutation status in Japanese lung cancer patients. Int J Cancer. 118:180–184. 2006. View Article : Google Scholar : PubMed/NCBI
14	Sasaki H, Endo K, Konishi A, et al: EGFR mutation status in Japanese lung cancer patients: genotyping analysis using LighyCycler. Clin Cancer Res. 11:2924–2929. 2005. View Article : Google Scholar : PubMed/NCBI
15	Smith IM, Mithani SK, Liu C, et al: Novel integrative methods for gene discovery associated with head and neck squamous cell carcinoma development. Arch Otolaryngol Head Neck Surg. 135:487–495. 2009. View Article : Google Scholar : PubMed/NCBI
16	Nakata S, Sugio K, Uramoto H, et al: The methylation status and protein expression of CDH1, p16INK4A, and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance. Cancer. 106:2190–2199. 2006. View Article : Google Scholar
17	Ying J, Poon FF, Yu J, et al: DLEC1 is a functional 3p22.3 tumor suppressor silenced by promoter CpG methylation in colon and gastric cancers. Br J Cancer. 100:663–669. 2009. View Article : Google Scholar : PubMed/NCBI
18	Jarmalaite S, Kannio A, Anttila S, et al: Aberrant p16 promoter methylation in smokers and former smokers with non-small cell lung cancer. Int J Cancer. 106:913–918. 2003. View Article : Google Scholar : PubMed/NCBI
19	Kim DH, Nelson HH, Wiencke JK, et al: p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. Cancer Res. 61:3419–3424. 2001.PubMed/NCBI
20	Rom WN, Jay JG, Lee TC, Jiang Y and Tchou-Wong KM: Molecular and genetic aspects of lung cancer. Am J Respir Crit Care Med. 161:1355–1367. 2000. View Article : Google Scholar : PubMed/NCBI
21	Swafford DS, Middleton SK, Palmisano WA, et al: Frequent aberrant methylation of p16INK4a in primary rat lung tumors. Mol Cell Biol. 17:1366–1374. 1997.PubMed/NCBI
22	Kim DS, Kim MJ, Lee JY, et al: Aberrant methylation of E-cadherin and H-cadherin genes in non-small cell lung cancer and its relation to clinicopathologic features. Cancer. 110:2785–2792. 2007. View Article : Google Scholar : PubMed/NCBI
23	Ma BB, Sung F, Tao Q, et al: The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines. Invest New Drugs. Jan 27–2009.(Epub ahead of print).
24	Takai N, Kawamata N, Gui D, Said JW, Miyakawa I and Koeffler HP: Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis. Cancer. 15:2760–2770. 2004. View Article : Google Scholar